EX-99.1 2 ex991to22120198kresupple.htm EXHIBIT 99.1 ex991to22120198kresupple
Schedule of Segment Revenues Three Months Ended % Increase / (Decrease) April 1, 2018 April 2, 2017 Total Currency Constant Currency Americas $ 323.3 $ 260.8 24.0% 0.4% 23.6% EMEA 159.9 133.6 19.7% 15.1% 4.6% Asia 58.2 50.2 16.1% 7.0% 9.1% OEM 45.8 43.3 5.8% 2.9% 2.9% Net revenues $ 587.2 $ 487.9 20.4% 5.8% 14.6% Three Months Ended % Increase / (Decrease) July 1, 2018 July 2, 2017 Total Currency Constant Currency Americas $ 331.5 $ 279.0 18.8% 0.1% 18.7% EMEA 153.4 138.5 10.8% 8.0% 2.8% Asia 72.4 66.0 9.7% 3.8% 5.9% OEM 52.6 45.1 16.5% 1.6% 14.9% Net revenues $ 609.9 $ 528.6 15.4% 3.0% 12.4% Three Months Ended % Increase / (Decrease) September 30, 2018 October 1, 2017 Total Currency Constant Currency Americas $ 338.7 $ 274.9 23.2% -0.4% 23.6% EMEA 139.6 137.0 1.8% -1.1% 2.9% Asia 76.5 74.2 3.2% -3.5% 6.7% OEM 54.9 48.6 12.9% -0.2% 13.1% Net revenues $ 609.7 $ 534.7 14.0% -1.0% 15.0% Three Months Ended % Increase / (Decrease) December 31, 2018 December 31, 2017 Total Currency Constant Currency Americas $ 358.2 $ 326.7 9.6% -0.3% 9.9% EMEA 150.9 143.6 5.1% -3.1% 8.2% Asia 79.8 78.8 1.1% -4.4% 5.5% OEM 52.7 46.0 14.8% -0.6% 15.4% Net revenues $ 641.6 $ 595.1 7.8% -1.6% 9.4% Twelve Months Ended % Increase / (Decrease) December 31, 2018 December 31, 2017 Total Currency Constant Currency Americas $ 1,351.7 $ 1,141.4 18.4% -0.1% 18.5% EMEA 603.8 552.7 9.2% 4.6% 4.6% Asia 286.9 269.2 6.6% 0.0% 6.6% OEM 206.0 183.0 12.6% 0.9% 11.7% Net revenues $ 2,448.4 $ 2,146.3 14.1% 1.4% 12.7% Twelve Months Ended % Increase / (Decrease) December 31, 2017 December 31, 2016 Total Currency Constant Currency Americas $ 1,141.4 $ 946.7 20.6% 0.2% 20.4% EMEA 552.7 510.9 8.2% 1.9% 6.3% Asia 269.2 249.4 7.9% 0.9% 7.0% OEM 183.0 161.0 13.7% 0.5% 13.2% Net revenues $ 2,146.3 $ 1,868.0 14.9% 0.8% 14.1%


 
Schedule of Global Product Revenues Three Months Ended % Increase / (Decrease) April 1, 2018 April 2, 2017 Total Currency Constant Currency Vascular access 144.1 130.4 10.5% 4.2% 6.3% Anesthesia 84.9 80.8 5.1% 6.3% -1.2% Interventional 90.1 59.4 52.0% 4.2% 47.8% Surgical 85.6 87.3 -1.9% 5.0% -6.9% Interventional urology 42.3 - nm nm nm OEM 45.8 43.3 5.8% 2.9% 2.9% Other* 94.4 86.7 8.8% 7.9% 0.9% Net revenues $ 587.2 $ 487.9 20.4% 5.8% 14.6% Three Months Ended % Increase / (Decrease) July 1, 2018 July 2, 2017 Total Currency Constant Currency Vascular access 140.2 133.7 4.9% 2.1% 2.8% Anesthesia 89.3 85.6 4.3% 3.5% 0.8% Interventional 98.2 86.0 14.2% 1.5% 12.7% Surgical 90.5 90.7 -0.3% 3.0% -3.3% Interventional urology 47.7 - nm nm nm OEM 52.6 45.1 16.5% 1.6% 14.9% Other* 91.4 87.5 4.5% 4.2% 0.3% Net revenues $ 609.9 $ 528.6 15.4% 3.0% 12.4% Three Months Ended % Increase / (Decrease) September 30, 2018 October 1, 2017 Total Currency Constant Currency Vascular access 142.1 133.8 6.1% -1.0% 7.1% Anesthesia 87.5 87.5 0.0% -1.3% 1.3% Interventional 100.0 89.9 11.2% -0.6% 11.8% Surgical 89.9 85.2 5.5% -1.1% 6.6% Interventional urology 49.0 - nm nm nm OEM 54.9 48.6 12.9% -0.2% 13.1% Other* 86.3 89.7 -3.7% -1.1% -2.6% Net revenues $ 609.7 $ 534.7 14.0% -1.0% 15.0% Three Months Ended % Increase / (Decrease) December 31, 2018 December 31, 2017 Total Currency Constant Currency Vascular access 149.0 142.3 4.7% -1.5% 6.2% Anesthesia 87.7 90.7 -3.4% -1.9% -1.5% Interventional 107.1 89.4 19.7% -1.0% 20.7% Surgical 92.7 92.9 -0.3% -1.9% 1.6% Interventional urology 57.7 39.0 48.3% -0.2% 48.5% OEM 52.7 46.0 14.8% -0.6% 15.4% Other* 94.7 94.8 -0.1% -2.2% 2.1% Net revenues $ 641.6 $ 595.1 7.8% -1.6% 9.4% Twelve Months Ended % Increase / (Decrease) December 31, 2018 December 31, 2017 Total Currency Constant Currency Vascular access 575.4 540.2 6.5% 0.9% 5.6% Anesthesia 349.4 344.6 1.4% 1.6% -0.2% Interventional 395.4 324.7 21.8% 0.6% 21.2% Surgical 358.7 356.1 0.7% 1.4% -0.7% Interventional urology 196.7 39.0 405.0% -0.7% 405.7% OEM 206.0 183.0 12.6% 0.9% 11.7% Other* 366.8 358.7 2.3% 2.1% 0.2% Net revenues $ 2,448.4 $ 2,146.3 14.1% 1.4% 12.7% * Other includes revenues generated from sales of the Company's respiratory and urology products Certain reclassifications were made to prior interim periods to conform to the presentation in the 2018 Form 10-K Certain financial information is presented on a rounded basis, which may cause minor differences